Lapaquistat acetate (diet supplemented; 100 or 200 mg/kg; 32 weeks) decreases plasma cholesterol and triglyceride levels. It delays progression of coronary atherosclerosis and changes coronary atheromatous plaques from unstable, macrophage/lipid accumulation-rich, lesions to stable fibromuscular lesions in vivo[3].
| Animal Model: | Male WHHLMI rabbits, aged 2 months[3] |
| Dosage: | 100 or 200mg/kg |
| Administration: | Diet supplemented; 100 or 200mg/kg; 32 weeks |
| Result: | Increased collagen concentration and transformed coronary plaques into fibromuscular plaques.
Suppressed the expression of MMP-1 and PAI-1 in the plaque and increased peripheral coenzyme Q10 levels. |
